US says 'no concerns' with vaccines eyed in Japan deaths

Mar 07, 2011

US health officials said Monday they have had no reports that arouse new safety concerns over two children's vaccines that have been suspended in Japan following the deaths of four babies.

Researchers at the (FDA) and (CDC) "have not detected new safety concerns or unusual reporting patterns" among children given the vaccines against bacteria that can cause meningitis and pneumonia, FDA spokeswoman Shelly Burgess said.

Japanese health authorities ordered doctors to stop using the two vaccines -- Prevenar, made by US-based Pfizer, and ActHIB, made by the Sanofi Pasteur wing of Paris-headquartered Sanofi-Aventis -- following the deaths of four infants who were given the shots alone or in combination with others drugs.

The infants, aged from around six months to under two years old, all died between March 2 and 4, Japanese officials said.

In addition to the four cases, Japan's health ministry said another infant died in November after receiving his second shot of the ActHIB , a Japanese health ministry official said.

The FDA and CDC are aware of the babies' deaths and of the suspension of the two vaccines in , a statement sent by Burgess to AFP said.

US health agencies were continuing to monitor the safety of all vaccines, including those against the haemophilus influenzae type b (Hib) bacteria and streptococcus pneumoniae targeted by ActHIB and Prevenar, the statement said.

Explore further: India's meth addiction grows as criminals tap chemical hub

add to favorites email to friend print save as pdf

Related Stories

Kids' Swine flu shots recalled; not strong enough

Dec 15, 2009

(AP) -- Hundreds of thousands of swine flu shots for children have been recalled because tests indicate the vaccine doses lost some strength, government health officials said Tuesday.

WHO: nearly 5,000 swine flu deaths worldwide

Oct 23, 2009

(AP) -- Nearly 5,000 people have reportedly died from swine flu since it emerged this year and developed into a global epidemic, the World Health Organization said Friday.

Recommended for you

Determine patient preferences by means of conjoint analysis

Jul 29, 2014

The Conjoint Analysis (CA) method is in principle suitable to find out which preferences patients have regarding treatment goals. However, to widely use it in health economic evaluations, some (primarily methodological) issues ...

FDA approves hard-to-abuse narcotic painkiller

Jul 25, 2014

(HealthDay)—A new formulation of a powerful narcotic painkiller that discourages potential abusers from snorting or injecting the drug has been approved by the U.S. Food and Drug Administration.

Race affects opioid selection for cancer pain

Jul 25, 2014

(HealthDay)—Racial disparities exist in the type of opioid prescribed for cancer pain, according to a study published online July 21 in the Journal of Clinical Oncology.

FDA approves tough-to-abuse formulation of oxycodone

Jul 25, 2014

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe ...

User comments : 1

Adjust slider to filter visible comments by rank

Display comments: newest first

Caliban
not rated yet Mar 07, 2011
What is the sample size? Are 5 fatalities of any statistical relevance? Why the sketchy info -almost zero context.